{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:27:36Z","timestamp":1789687656471,"version":"4.0.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,3,10]],"date-time":"2027-03-10T00:00:00Z","timestamp":1804636800000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["546185154"],"award-info":[{"award-number":["546185154"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011345"],"award-info":[{"award-number":["ZIA BC 011345"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011870"],"award-info":[{"award-number":["ZIA BC 011870"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011343"],"award-info":[{"award-number":["ZIA BC 011343"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.smim.2025.102000","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:45:26Z","timestamp":1773182726000},"page":"102000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chimeric antigen receptor therapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"81","author":[{"given":"Lorenz","family":"Kocheise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Reda","family":"Benmebarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-2535","authenticated-orcid":false,"given":"Tim F.","family":"Greten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR t cell therapy to solid tumors","volume":"43","author":"Uslu","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib5","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"issue":"8047","key":"10.1016\/j.smim.2025.102000_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR t cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"issue":"16_","key":"10.1016\/j.smim.2025.102000_bib7","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2024.42.16_suppl.4019","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib8","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib9","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-Specific chimeric antigen Receptor-Engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2025.102000_bib12","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of Anti-GPC3 chimeric antigen Receptor-Modified natural killer cells against hepatocellular cancer cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag Res."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib13","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"issue":"16_","key":"10.1016\/j.smim.2025.102000_bib14","article-title":"Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma","volume":"40","author":"Shaik","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.smim.2025.102000_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003441","article-title":"Off-the-shelf Vdelta1 gamma delta t cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib16","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","article-title":"Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy","volume":"209","author":"Dogan","year":"2022","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib17","article-title":"Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions","volume":"3","author":"Healy","year":"2021","journal-title":"JHEP Rep."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting t cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.smim.2025.102000_bib19","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.smim.2025.102000_bib20","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib22","article-title":"264 development of allogeneic, potency-edited, anti-GPC3 CAR-T cells for the treatment of hepatocellular carcinoma","volume":"11","author":"Dan","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.102000_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104748","article-title":"Adoptive T-cell therapy for HBV-associated HCC and HBV infection","volume":"176","author":"Tan","year":"2020","journal-title":"Antivir. Res"},{"key":"10.1016\/j.smim.2025.102000_bib24","doi-asserted-by":"crossref","unstructured":"Maravelia P., Yao H., Cai C., Nascimento Silva D., Fransson J., Nilsson O.B., et al. Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation. Gut. 2025.","DOI":"10.1136\/gutjnl-2024-334148"},{"issue":"6230","key":"10.1016\/j.smim.2025.102000_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"10435","key":"10.1016\/j.smim.2025.102000_bib26","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"791","key":"10.1016\/j.smim.2025.102000_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado9371","article-title":"CAR T cells based on fully human t cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo","volume":"17","author":"Salzler","year":"2025","journal-title":"Sci. Transl. Med"},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib29","article-title":"Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Sci. Rep."},{"issue":"38","key":"10.1016\/j.smim.2025.102000_bib30","doi-asserted-by":"crossref","first-page":"41339","DOI":"10.18632\/oncotarget.5463","article-title":"A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.smim.2025.102000_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jhep.2018.10.040","article-title":"Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma","volume":"70","author":"Yu","year":"2019","journal-title":"J. Hepatol."},{"issue":"4_","key":"10.1016\/j.smim.2025.102000_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/JCO.2025.43.4_suppl.518","article-title":"Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: extended follow-up of a randomized controlled trial and post-treatment immune cell profiling","volume":"43","author":"Lee","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib34","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1053\/j.gastro.2020.02.011","article-title":"Persistent polyfunctional chimeric antigen receptor t cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice","volume":"158","author":"Li","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/hum.2016.025","article-title":"Redirecting t cells to Glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity","volume":"28","author":"Li","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"24","key":"10.1016\/j.smim.2025.102000_bib36","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of t cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.smim.2025.102000_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1309\/HCQWPWD50XHD2DW6","article-title":"Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples","volume":"129","author":"Baumhoer","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.smim.2025.102000_bib39","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical wnt signaling","volume":"65","author":"Capurro","year":"2005","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib40","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/hep.30646","article-title":"A Frizzled-Like Cysteine-Rich domain in Glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice","volume":"70","author":"Li","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.smim.2025.102000_bib41","article-title":"Epitope mapping by a Wnt-blocking antibody: evidence of the wnt binding domain in heparan sulfate","volume":"6","author":"Gao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2025.102000_bib42","article-title":"Human t cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice","author":"Vercher","year":"2024","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib43","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2015.05.055","article-title":"T cells engineered to express a T-Cell receptor specific for Glypican-3 to recognize and kill hepatoma cells in vitro and in mice","volume":"149","author":"Dargel","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.smim.2025.102000_bib45","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2025.03.017","article-title":"Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity","volume":"188","author":"Kondo","year":"2025","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.smim.2025.102000_bib46","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib47","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J. Transl. Med"},{"issue":"6","key":"10.1016\/j.smim.2025.102000_bib48","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/08820139.2023.2232402","article-title":"HGF-Based CAR-T cells target hepatocellular carcinoma cells that express high levels of c-Met","volume":"52","author":"Ma","year":"2023","journal-title":"Immunol. Invest"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib49","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-016-1949-8","article-title":"Development of t cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.smim.2025.102000_bib50","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.7150\/ijms.45603","article-title":"EGFRvIII-specific CAR-T cells produced by piggybac transposon exhibit efficient growth suppression against hepatocellular carcinoma","volume":"17","author":"Ma","year":"2020","journal-title":"Int J. Med Sci."},{"issue":"11","key":"10.1016\/j.smim.2025.102000_bib51","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of hepatocellular carcinoma by NKG2D-Based CAR-T cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib52","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial Antigen-Sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib53","article-title":"CD147-CAR-NK cell therapy shows minimal toxicities in human CD147 transgenic mouse model with solid tumors","volume":"33","author":"Sabha","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib54","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma","volume":"32","author":"Zhou","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.smim.2025.102000_bib55","article-title":"In vivo anti-FAP CAR t therapy reduces fibrosis and restores liver homeostasis in metabolic dysfunction-associated steatohepatitis","author":"Yashaswini","year":"2025","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib56","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scfv by CD133-specific CAR-T cells using nonviral sleeping beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.smim.2025.102000_bib57","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3389\/fonc.2020.01316","article-title":"New blood biomarkers for the diagnosis of AFP-Negative hepatocellular carcinoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib58","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting Alpha-Fetoprotein (AFP)-MHC complex with CAR T-Cell therapy for liver cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib59","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.29844","article-title":"Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy","volume":"68","author":"Zhu","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib60","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/hep.30477","article-title":"Tuning T-Cell receptor affinity to optimize clinical risk-benefit when targeting Alpha-fetoprotein-positive liver cancer","volume":"69","author":"Docta","year":"2019","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib61","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/lt.26431","article-title":"Assessment of human leukocyte antigen matching algorithm PIRCHE-II on liver transplantation outcomes","volume":"28","author":"Kok","year":"2022","journal-title":"Liver Transpl."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12185-023-03621-y","article-title":"Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation","volume":"118","author":"Barakat","year":"2023","journal-title":"Int J. Hematol."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib63","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2014.10.001","article-title":"Immunotherapy of HCC metastases with autologous T cell receptor redirected t cells, targeting HBsAg in a liver transplant patient","volume":"62","author":"Qasim","year":"2015","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.smim.2025.102000_bib64","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","article-title":"Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy","volume":"156","author":"Tan","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.smim.2025.102000_bib65","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.smim.2025.102000_bib66","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"24","key":"10.1016\/j.smim.2025.102000_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi5781","article-title":"Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors","volume":"7","author":"Cadilha","year":"2021","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib68","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep. Med"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib69","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib70","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s10238-024-01473-2","article-title":"IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma","volume":"24","author":"Chen","year":"2024","journal-title":"Clin. Exp. Med"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","article-title":"A novel engineered IL-21 receptor arms T-cell receptor-engineered t cells (TCR-T cells) against hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.smim.2025.102000_bib73","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1158\/1538-7445.AM2023-2902","article-title":"Abstract 2902: Off-the-Shelf CAR-NK cells engineered to express calibrated release IL-15 exhibit enhanced persistence and anti-tumor activities","volume":"83","author":"Lee","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.smim.2025.102000_bib74","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omto.2022.04.003","article-title":"Chimeric anti-GPC3 sFv-CD3epsilon receptor-modified T cells with IL7 co-expression for the treatment of solid tumors","volume":"25","author":"Sun","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.smim.2025.102000_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2025.102000_bib76","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the Anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharm."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib77","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD\u20111 CAR\u2011T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int J. Oncol."},{"issue":"10","key":"10.1016\/j.smim.2025.102000_bib78","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-018-2221-1","article-title":"Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein","volume":"67","author":"Pan","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.smim.2025.102000_bib79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/imm.13624","article-title":"Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma","volume":"169","author":"Chen","year":"2023","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib80","first-page":"A68","article-title":"109\u2005Dominant-negative TGF\u03b2 receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma","volume":"8","author":"Chu","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12967-023-04829-6","article-title":"DNTGF-betaR armored CAR-T cell therapy against tumors from bench to bedside","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib82","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated t cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib84","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1038\/s41467-025-59529-0","article-title":"SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases","volume":"16","author":"Trehan","year":"2025","journal-title":"Nat. Commun."},{"issue":"52","key":"10.1016\/j.smim.2025.102000_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory t cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib86","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"Shiri","year":"2024","journal-title":"J. Hepatol."},{"issue":"6730","key":"10.1016\/j.smim.2025.102000_bib87","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1126\/science.adl4100","article-title":"Bile acid synthesis impedes tumor-specific t cell responses during liver cancer","volume":"387","author":"Varanasi","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.smim.2025.102000_bib88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev. Biol."},{"issue":"10","key":"10.1016\/j.smim.2025.102000_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7854","key":"10.1016\/j.smim.2025.102000_bib90","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"7593","key":"10.1016\/j.smim.2025.102000_bib91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) t lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib92","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2022.03.010","article-title":"Metformin treatment rescues CD8(+) T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD","volume":"77","author":"Wabitsch","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41467-020-20422-7","article-title":"Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma","volume":"12","author":"Behary","year":"2021","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.smim.2025.102000_bib94","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.cell.2021.09.019","article-title":"Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment","volume":"184","author":"Lam","year":"2021","journal-title":"Cell"},{"issue":"6371","key":"10.1016\/j.smim.2025.102000_bib95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib96","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41420-025-02413-z","article-title":"Roles of the gut microbiota in hepatocellular carcinoma: from the gut dysbiosis to the intratumoral microbiota","volume":"11","author":"Wang","year":"2025","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib97","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR t cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib98","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib99","article-title":"Hepatic immune environment differences among common mouse strains in models of MASH and liver cancer","volume":"7","author":"Huang","year":"2025","journal-title":"JHEP Rep."},{"issue":"7684","key":"10.1016\/j.smim.2025.102000_bib100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature24993","article-title":"Runx3 programs CD8(+) t cell residency in non-lymphoid tissues and tumours","volume":"552","author":"Milner","year":"2017","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.smim.2025.102000_bib101","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.smim.2025.102000_bib102","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1200\/JCO.2024.42.16_suppl.2543","article-title":"Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors","volume":"42","author":"Nakajima","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib103","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"issue":"20","key":"10.1016\/j.smim.2025.102000_bib104","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib105","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"3","key":"10.1016\/j.smim.2025.102000_bib106","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","article-title":"Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: the impact of successful antiviral treatment","volume":"81","author":"Celsa","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib107","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/hep.31662","article-title":"Immunosuppressive Drug-Resistant armored T-Cell receptor T cells for immune therapy of HCC in liver transplant patients","volume":"74","author":"Hafezi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.smim.2025.102000_bib108","article-title":"GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay","volume":"31","author":"Cao","year":"2022","journal-title":"Biochem Biophys. Rep."},{"issue":"11","key":"10.1016\/j.smim.2025.102000_bib109","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00262-012-1278-5","article-title":"B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence","volume":"61","author":"Sun","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"35","key":"10.1016\/j.smim.2025.102000_bib110","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.23.02229","article-title":"STRIvE-02: a First-in-Human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with Relapsed\/Refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2025.102000_bib111","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","article-title":"Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.smim.2025.102000_bib112","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.smim.2025.102000_bib113","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41596-020-0294-8","article-title":"Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands","volume":"15","author":"Chang","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.smim.2025.102000_bib114","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.omtm.2019.05.002","article-title":"In-Depth characterization of a Mifepristone-Regulated expression system for AAV5-Mediated gene therapy in the liver","volume":"13","author":"Liefhebber","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"14","key":"10.1016\/j.smim.2025.102000_bib115","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of Intra-Arterial chimeric antigen Receptor-Modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res"},{"issue":"6476","key":"10.1016\/j.smim.2025.102000_bib116","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.smim.2025.102000_bib117","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.smim.2025.102000_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1346764","article-title":"Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma","volume":"6","author":"Tsuchiya","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2025.102000_bib119","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1538-7445.AM2022-2824","article-title":"Abstract 2824: engineered human IL-2\/IL-2Rb orthogonal pairs selectively enhance anti-GPC3 CAR T cells to drive complete responses in solid epithelial tumor models","volume":"82","author":"Aspuria","year":"2022","journal-title":"Cancer Res."},{"issue":"6379","key":"10.1016\/j.smim.2025.102000_bib120","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"issue":"625","key":"10.1016\/j.smim.2025.102000_bib121","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR t cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532325000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:25:50Z","timestamp":1777605950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532325000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":121,"alternative-id":["S1044532325000727"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2025.102000","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor therapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2025.102000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102000"}}